<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0185-3325</journal-id>
<journal-title><![CDATA[Salud mental]]></journal-title>
<abbrev-journal-title><![CDATA[Salud Ment]]></abbrev-journal-title>
<issn>0185-3325</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0185-33252020000200065</article-id>
<article-id pub-id-type="doi">10.17711/sm.0185-3325.2020.010</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Cost-effectiveness analysis of interventions to achieve universal health coverage for schizophrenia in Mexico]]></article-title>
<article-title xml:lang="es"><![CDATA[Análisis costo-efectividad de las intervenciones para alcanzar la cobertura universal en salud para esquizofrenia en México]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cabello-Rangel]]></surname>
<given-names><![CDATA[Héctor]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz-Castro]]></surname>
<given-names><![CDATA[Lina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pineda-Antúnez]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Psiquiátrico Fray Bernardino Álvarez  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Psiquiatría Ramón de la Fuente Muñíz Dirección de Investigaciones Epidemiológicas y Psicosociales ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Salud Pública Departamento de Investigación de Servicios de Salud ]]></institution>
<addr-line><![CDATA[Cuernavaca Morelos]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2020</year>
</pub-date>
<volume>43</volume>
<numero>2</numero>
<fpage>65</fpage>
<lpage>71</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0185-33252020000200065&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0185-33252020000200065&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0185-33252020000200065&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction To achieve universal coverage in mental health, it is necessary to demonstrate which interventions should be adopted.  Objective Analyze the alternatives of pharmacological and psychosocial treatment in Mexico for patients diagnosed with schizophrenia, as well as Early Intervention in Psychosis Program.  Method The Extended cost effectiveness analysis (ECEA), it is implemented under scenario the option of treatment in Mexico, which includes: typical or atypical antipsychotic medication plus psychosocial treatment, assuming that all the medications will be provided to the patient, a measure of effectiveness is the years of life adjusted to disability (DALYs).  Results The effect of Universal Public Financing (UPF) is reflected in avoiding 147 DALYs for every 1,000,000 habitants. In addition, has a positive effect in the avoided pocket expenditures from US $ 101,221 to US $ 787,498 according to the type of intervention. Increasing government spending has a greater impact on the poorest quintile, as a distributive effect of the budget is generated. Respect to the value of insurance, the quintile III is the one who is most willing to pay for having insurance, on the other hand, in the highest income quintile, the minimum assurance valuation was observed.  Discussion and conclusion The reduction in out-of-pocket spending is uniform across all quintiles; &#8220;Early Intervention in Psychosis Program&#8221; is not viable for middle income countries, as México. The ECEA is a convenient method to assess the feasibility and affordability of mental health interventions to generate information for decision makers.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción Para lograr la cobertura universal en salud mental es necesario demostrar qué intervenciones deberían ser adoptadas.  Objetivo Analizar las alternativas de tratamiento farmacológico y psicosocial para pacientes con esquizofrenia incluidas, así como un Programa de Intervención Temprana en Psicosis.  Método El análisis costo efectividad extendido (ECEA) se implementó bajo un escenario que incluye: medicación antipsicótica típica o atípica más tratamiento psicosocial, asumiendo que todos los medicamentos serán provistos a los pacientes, la medición de la efectividad en términos de DALYs.  Resultados El efecto del financiamiento público universal se refleja en evitar 147 DALYs por cada 1, 000,000 de habitantes. Además, tiene un efecto positivo en evitar pagos de bolsillo de US $ 101,221 a US $ 787,478 de acuerdo con el tipo de intervención. Incrementar el gasto del gobierno tiene un gran impacto sobre los quintiles más pobres como efecto distributivo del presupuesto. El quintil III de ingreso tiene mayor disposición a pagar el aseguramiento mientras que el quintil más rico tiene menor disposición a pagarlo.  Discusión y conclusión La reducción de los gastos de bolsillo es uniforme en todos los quintiles de ingreso, pero el &#8220;Programa de Intervención Temprana en Psicosis&#8221; no es viable generalizarlo para países de ingreso medio, como México. El ECEA es un método conveniente para evaluar la factibilidad y asequibilidad de intervenciones en salud mental para generar información para los tomadores de decisiones.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Universal health coverage]]></kwd>
<kwd lng="en"><![CDATA[schizophrenia]]></kwd>
<kwd lng="en"><![CDATA[cost-effectiveness]]></kwd>
<kwd lng="es"><![CDATA[Cobertura universal en salud]]></kwd>
<kwd lng="es"><![CDATA[esquizofrenia]]></kwd>
<kwd lng="es"><![CDATA[costo-efectividad]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brigham]]></surname>
<given-names><![CDATA[E. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Houston]]></surname>
<given-names><![CDATA[J. F.]]></given-names>
</name>
</person-group>
<source><![CDATA[Fundamentals of financial management]]></source>
<year>2005</year>
<edition>10th Edition</edition>
<publisher-name><![CDATA[Ed Thomson]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cabello-Rangel]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz-Castro]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Arredondo]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Costo-efectividad de intervenciones para esquizofrenia en México]]></article-title>
<source><![CDATA[Salud Mental]]></source>
<year>2011</year>
<volume>34</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>95-102</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chatterjee]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Naik]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[John]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Dabholkar]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Balaji]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Koschorke]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Thornicroft]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of a community-based intervention for people with schizophrenia and their caregivers in India (COPSI): A randomized controlled trail]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2014</year>
<volume>383</volume>
<numero>9926</numero>
<issue>9926</issue>
<page-range>1385-94</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chisholm]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Choosing cost-effective interventions in psychiatry: Results from the CHOICE programme of the World Health Organization]]></article-title>
<source><![CDATA[World Psychiatry]]></source>
<year>2005</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>37-44</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chisholm]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Saxena]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost effectiveness of strategies to combat neuropsychiatric conditions in sub-Saharan Africa and South East Asia: mathematical modelling study]]></article-title>
<source><![CDATA[British Medical Journal]]></source>
<year>2012</year>
<volume>344</volume>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="">
<collab>Institute for Health Metrics</collab>
<source><![CDATA[Global Burned Diseases]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="">
<collab>Instituto Mexicano del Seguro Social</collab>
<source><![CDATA[Documentación compra consolidada 2016-2017]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kohn]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Levav]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Caldas de Almeida]]></surname>
<given-names><![CDATA[J. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Vicente]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Silveira Guerra Andrade]]></surname>
<given-names><![CDATA[L. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Caraveo-Anduaga]]></surname>
<given-names><![CDATA[J. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Saxena]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Saraceno]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mental disorders in Latin America and the Caribbean: a public health priority]]></article-title>
<source><![CDATA[Revista Panamericana de Salud Pública]]></source>
<year>2005</year>
<volume>18</volume>
<numero>4-5</numero>
<issue>4-5</issue>
<page-range>229-40</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lara-Muñoz]]></surname>
<given-names><![CDATA[M. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Robles-García]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Orozco]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Saltijeral Méndez]]></surname>
<given-names><![CDATA[M. T.]]></given-names>
</name>
<name>
<surname><![CDATA[Medina-Mora]]></surname>
<given-names><![CDATA[M. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Chisholm]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio de costo-efectividad del tratamiento de la esquizofrenia en México]]></article-title>
<source><![CDATA[Salud Mental]]></source>
<year>2010</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>211-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leucht]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Pitschel-Walz]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Kissling]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials]]></article-title>
<source><![CDATA[Schizophrenia Research]]></source>
<year>1999</year>
<volume>35</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>51-68</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lora]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Kohn]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Levav]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[McBain]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Saxena]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Service availability and utilization and treatment gap for schizophrenic disorders: a survey in 50 low- and middle-income countries]]></article-title>
<source><![CDATA[Bulletin of the World Health Organization]]></source>
<year>2012</year>
<volume>90</volume>
<page-range>47-54B</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCrone]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Knapp]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Dhanasiri]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic impact of services for first-episode psychosis: A decision model approach]]></article-title>
<source><![CDATA[Early Intervention in Psychiatry]]></source>
<year>2009</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>266-73</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Universal health coverage for schizophrenia: A global mental health priority]]></article-title>
<source><![CDATA[Schizophrenia Bulletin]]></source>
<year>2016</year>
<volume>42</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>885-90</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raykar]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Nigam]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Chisholm]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance]]></article-title>
<source><![CDATA[Cost Effectiveness and Resource Allocation]]></source>
<year>2015</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>9</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="">
<collab>Secretaria de Salud</collab>
<source><![CDATA[Sistema de Protección Social en Salud. Elementos conceptuales, financieros y operativos]]></source>
<year>2005</year>
<publisher-loc><![CDATA[México, DF ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solmi]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Mohammadi]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Hameed]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[P. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Kirkbride]]></surname>
<given-names><![CDATA[J. B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictors of disengagement from Early Intervention in Psychosis services]]></article-title>
<source><![CDATA[The British Journal of Psychiatry]]></source>
<year>2018</year>
<volume>213</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>477-83</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thieda]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Beard]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Richter]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Kane]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An economic review of compliance with medication therapy in treatment of schizophrenia]]></article-title>
<source><![CDATA[Psychiatric Services]]></source>
<year>2003</year>
<volume>54</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>508-16</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="">
<collab>Union Nations Organization</collab>
<source><![CDATA[Sustainable Development Goals 2030]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Genève Switzerland ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verguet]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Laxminarayan]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Jamison]]></surname>
<given-names><![CDATA[D. T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Universal public finance of tuberculosis treatment in India: An extended cost-effectiveness analysis]]></article-title>
<source><![CDATA[Health Economics]]></source>
<year>2015</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>318-32</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whiteford]]></surname>
<given-names><![CDATA[H. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Degenhardt]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Rehm]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Baxter]]></surname>
<given-names><![CDATA[A. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[A. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Erskine]]></surname>
<given-names><![CDATA[H. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Vos]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2013</year>
<volume>382</volume>
<numero>9904</numero>
<issue>9904</issue>
<page-range>1575-86</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wirtz]]></surname>
<given-names><![CDATA[V. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Santa-Ana-Tellez]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Servan-Mori]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Avila-Burgos]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heterogeneous effects of health insurance on out-of-pocket expenditure on medicines in Mexico]]></article-title>
<source><![CDATA[Value in Health]]></source>
<year>2012</year>
<volume>15</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>593-603</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="">
<source><![CDATA[World Bank]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[Investing in mental health: evidence for action]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Geneva, Switzerland ]]></publisher-loc>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
